AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17083767 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with methotrexate, sulphasalazine, and tapered high dose of prednisone
Number of subjects: 508
Study 17083767 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with methotrexate and infliximab
Number of subjects: 508
Study 17083767 — intervention group
Group type: COMPARATOR
Intervention: Sequential monotherapy
Number of subjects: 508
Study 17083767 — intervention group
Group type: COMPARATOR
Intervention: Step up to combination therapy starting with methotrexate
Number of subjects: 508
Study 17083767 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment strategies
Number of subjects: 508
Study 14760157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis (CF)
Number of subjects: 302
Study 14760157 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 302
Study 11313304 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 59
Study 11313304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 11313304 — intervention group
Group type: EXPERIMENTAL
Intervention: pANCA
Number of subjects: 59
Study 11313304 — intervention group
Group type: EXPERIMENTAL
Intervention: sANCA
Number of subjects: 59
Study 11313304 — intervention group
Group type: EXPERIMENTAL
Intervention: LTA NcoI‐TNFc‐aa13L‐aa26 haplotype 1‐1‐1‐1
Number of subjects: 59
Study 9202949 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% glucose-electrolyte solution (GS)
Number of subjects: 6
Study 9202949 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% maltodextrin solution
Number of subjects: 6
Study 9202949 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% maltodextrin-electrolyte solution
Number of subjects: 6
Study 9202949 — intervention group
Group type: EXPERIMENTAL
Intervention: mineral water
Number of subjects: 6
Study 9202949 — intervention group
Group type: COMPARATOR
Intervention: No fluid (control)
Number of subjects: 6
Study 7956570 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal sphincter reconstruction using an overlapping muscle repair
Number of subjects: 14
Study 7956570 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous pull‐out manometric technique and PNTML
Number of subjects: 14
Study 7956570 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudendal nerve terminal motor latency (PNTML) assessment
Number of subjects: 14
Study 3440105 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg) given as enteric-coated granules
Number of subjects: 12
Study 3440105 — intervention group
Group type: COMPARATOR
Intervention: Antacid (10 ml, buffering capacity 56.6 mmol 10 ml‐1)
Number of subjects: 12
Study 31873772 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTNFR‐Fc plus MTX
Number of subjects: 466
Study 31873772 — intervention group
Group type: COMPARATOR
Intervention: rhTNFR‐Fc plus placebo
Number of subjects: 466
Study 31127974 — intervention group
Group type: EXPERIMENTAL
Intervention: PsychoEducation, Paced Respiration, and Relaxation (PEPRR)
Number of subjects: 155
Study 31127974 — intervention group
Group type: COMPARATOR
Intervention: enhanced treatment as usual (eTAU)
Number of subjects: 155
Study 27933462 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Beginning Initiative (HBI)
Number of subjects: 2498
Study 27933462 — intervention group
Group type: COMPARATOR
Intervention: Standard of care referral to a health facility (CG)
Number of subjects: 2498
Study 25946501 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 76
Study 25946501 — intervention group
Group type: EXPERIMENTAL
Intervention: Message
Number of subjects: 76
Study 25946501 — intervention group
Group type: COMPARATOR
Intervention: Silence (Control)
Number of subjects: 76
Study 23299762 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Running (HIIR) - 10 × 1 min running intervals at 100% maximal aerobic speed with 1 min recovery between intervals
Number of subjects: 15
Study 23299762 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - resting
Number of subjects: 15
Study 23299762 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Running (HIIR)
Number of subjects: 15
Study 21981454 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 0
Study 21981454 — intervention group
Group type: EXPERIMENTAL
Intervention: Mustard oil
Number of subjects: 0
Study 21981454 — intervention group
Group type: EXPERIMENTAL
Intervention: Olvanil
Number of subjects: 0
Study 21981454 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde
Number of subjects: 0
Study 21981454 — intervention group
Group type: EXPERIMENTAL
Intervention: Anandamide
Number of subjects: 0
Study 21981454 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol
Number of subjects: 0
Study 21981454 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 18665032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin ointment therapy
Number of subjects: 26
Study 18665032 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin ear drops
Number of subjects: 26
Study 16715358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose of pertuzumab (420 or 1050 mg)
Number of subjects: 153
Study 16715358 — intervention group
Group type: COMPARATOR
Intervention: Weight-based dosing (0.5-15 mg/kg)
Number of subjects: 153
Study 16715358 — intervention group
Group type: COMPARATOR
Intervention: BSA-based dosing
Number of subjects: 153
Study 12559533 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 1 x 300 mg as a loading dose, and 1 x 75 mg per day thereafter
Number of subjects: 158
Study 12559533 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine 2 x 250 mg daily
Number of subjects: 158
Study 11255054 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon5 (sodium hyaluronate 2.3%)
Number of subjects: 90
Study 11255054 — intervention group
Group type: COMPARATOR
Intervention: Viscoat (sodium hyaluronate 3.0%-chondroitin sulfate 4.0%)
Number of subjects: 90
Study 11255054 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon5
Number of subjects: 90
Study 11255054 — intervention group
Group type: COMPARATOR
Intervention: Viscoat
Number of subjects: 90
Study 11255054 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon5 and Viscoat
Number of subjects: 90
Study 9424002 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose radiation therapy (60 Gy continuously) and daily cisplatin (6 mg/sqm/day)
Number of subjects: 23
Study 8276050 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 12
Study 8276050 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 12
Study 8276050 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ramipril and propranolol
Number of subjects: 12
Study 3719066 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic
Number of subjects: 0
Study 3719066 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential test
Number of subjects: 0
Study 3719066 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional accumulated data
Number of subjects: 0
Study 30611113 — intervention group
Group type: EXPERIMENTAL
Intervention: The Pink Kit Method for Birthing Better® (CKT, 2001), a multi-media, skills-based and self-directed childbirth preparation programme.
Number of subjects: 182
Study 30611113 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified in detail).
Number of subjects: 182
Study 28391278 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote assessment via high-quality videoconferencing (HQ-VTC)
Number of subjects: 90
Study 28391278 — intervention group
Group type: COMPARATOR
Intervention: Bedside assessment
Number of subjects: 90
Study 28391278 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote assessment via HQ-VTC
Number of subjects: 90
Study 24907502 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose oral budesonide suspension (OBS)
Number of subjects: 71
Study 24907502 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral budesonide suspension (OBS)
Number of subjects: 71
Study 24907502 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral budesonide suspension (OBS)
Number of subjects: 71
Study 24907502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 23592260 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision (intervention group)
Number of subjects: 156
Study 23592260 — intervention group
Group type: COMPARATOR
Intervention: Uncircumcised (control group)
Number of subjects: 156
Study 21334854 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate 2mg/d
Number of subjects: 46
Study 21334854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 19050877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous mononuclear bone marrow cells (BMC)
Number of subjects: 39
Study 19050877 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study 17130431 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered CC chemokine receptor 1 (CCR1) antagonist
Number of subjects: 105
Study 17130431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 15313289 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured edge IOL (Alcon MA60AC)
Number of subjects: 54
Study 15313289 — intervention group
Group type: COMPARATOR
Intervention: Round-anterior, sloped-sided edge IOL (AMO AR40e)
Number of subjects: 54
Study 15313289 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 54
Study 10912264 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of nasal allergy for a period of at least four months
Number of subjects: 52
Study 9195540 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease targeted measures
Number of subjects: 0
Study 8141724 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirulog
Number of subjects: 400
Study 8141724 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 400
Study 2883406 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g/kg intravenous immunoglobulin
Number of subjects: 12
Study 2883406 — intervention group
Group type: COMPARATOR
Intervention: 0.2 g/kg intravenous immunoglobulin
Number of subjects: 12
Study 29916860 — intervention group
Group type: EXPERIMENTAL
Intervention: LAS VEGAS risk score
Number of subjects: 6063
Study 26700254 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue staining (Group 1)
Number of subjects: 144
Study 26700254 — intervention group
Group type: COMPARATOR
Intervention: No staining (Group 2)
Number of subjects: 144
Study 24215475 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) with light dose of 70 J/cm2
Number of subjects: 38
Study 24215475 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) with light dose of 100 J/cm2
Number of subjects: 38
Study 24215475 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events of ALA-PDT
Number of subjects: 38
Study 22503646 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and nutrition program for seniors (PANS)
Number of subjects: 248
Study 22503646 — intervention group
Group type: COMPARATOR
Intervention: Control group (small incentives for questionnaires)
Number of subjects: 248
Study 20102925 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D speckle tracking strain imaging system
Number of subjects: 64
Study 20102925 — intervention group
Group type: COMPARATOR
Intervention: Standard 2-D strain datasets
Number of subjects: 64
Study 18031294 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry-based VWF:RCo assay
Number of subjects: 84
Study 16120888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 10
Study 16120888 — intervention group
Group type: COMPARATOR
Intervention: Modified conventional glucose control
Number of subjects: 10
Study 16120888 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 10
Study 12115321 — intervention group
Group type: EXPERIMENTAL
Intervention: Perilymphatic recombinant IL‐2 (rIL‐2) administered at 5000 units daily for 10 days before surgery and monthly for 1 year after surgery.
Number of subjects: 202
Study 12115321 — intervention group
Group type: COMPARATOR
Intervention: Surgery and radiotherapy (Control group).
Number of subjects: 202
Study 10336919 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus losartan (group B)
Number of subjects: 99
Study 10336919 — intervention group
Group type: COMPARATOR
Intervention: Captopril (group A)
Number of subjects: 99
Study 10336919 — intervention group
Group type: COMPARATOR
Intervention: Losartan (group C)
Number of subjects: 99
Study 7579136 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 IU insulin kg‐1
Number of subjects: 8
Study 7579136 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 8
Study 1537779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (active treatment)
Number of subjects: 50
Study 1537779 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 50
Study 6393818 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 4-6 micrograms/kg
Number of subjects: 80
Study 6393818 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 80
Study 6393818 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 80
Study 30789780 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 308
Study 29377842 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based eye drops
Number of subjects: 30
Study 29377842 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate-based eye drops
Number of subjects: 30
Study 24048759 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically activated shears (UAS)
Number of subjects: 253
Study 24048759 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 253
Study 22613136 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab infusion
Number of subjects: 60
Study 22613136 — intervention group
Group type: COMPARATOR
Intervention: placebo infusion
Number of subjects: 60
Study 19272785 — intervention group
Group type: EXPERIMENTAL
Intervention: Posthorax sternum vest (group A)
Number of subjects: 455
Study 19272785 — intervention group
Group type: COMPARATOR
Intervention: No vest (group B)
Number of subjects: 455
Study 19272785 — intervention group
Group type: COMPARATOR
Intervention: No vest (group C)
Number of subjects: 455
Study 17697305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg/kg bolus and infusion at a rate of 0.7 microg/kg/h)
Number of subjects: 24
Study 17697305 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving dexmedetomidine)
Number of subjects: 24
Study 17697305 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (D and C)
Number of subjects: 24
Study 15352143 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized advice on non‐pharmacological strategies from an extended practice nurse
Number of subjects: 71
Study 15352143 — intervention group
Group type: COMPARATOR
Intervention: Usual care (assessment by a geriatrician)
Number of subjects: 71
Study 11642510 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum transferrin receptor (s‐TfR) levels in RA patients
Number of subjects: 50
Study 11642510 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum erythropoietin (EPO) levels in RA patients
Number of subjects: 50
Study 11642510 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of s‐TfR levels with red blood cell count, serum iron level, and haemoglobin concentration
Number of subjects: 50
Study 11642510 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of s‐TfR levels with ESR and serum EPO levels
Number of subjects: 50
Study 11642510 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of s‐TfR levels with markers of inflammation
Number of subjects: 50
Study 11367653 — intervention group
Group type: EXPERIMENTAL
Intervention: Feiyan Chuansou Oral Liquid (FCOL)
Number of subjects: 0
Study 7882780 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminal warm blood cardioplegia (TWBC)
Number of subjects: 69
Study 7882780 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous warm blood cardioplegia (CWBC)
Number of subjects: 69
Study 7882780 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia (CBC)
Number of subjects: 69
Study 7882780 — intervention group
Group type: COMPARATOR
Intervention: St. Thomas group (CC)
Number of subjects: 69
Study 2975567 — intervention group
Group type: EXPERIMENTAL
Intervention: Three times daily pen regimen with human ultralente at night
Number of subjects: 78
Study 2975567 — intervention group
Group type: COMPARATOR
Intervention: Twice daily insulin regimen
Number of subjects: 78
Study 29665013 — intervention group
Group type: EXPERIMENTAL
Intervention: N-BR (normoxic bed rest)
Number of subjects: 11
Study 29665013 — intervention group
Group type: EXPERIMENTAL
Intervention: H-BR (hypoxic bed rest)
Number of subjects: 11
Study 29665013 — intervention group
Group type: EXPERIMENTAL
Intervention: H-AMB (hypoxic ambulatory confinement)
Number of subjects: 11
Study 25952532 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-prandial insulin (stepwise addition of insulin glulisine)
Number of subjects: 0
Study 25952532 — intervention group
Group type: COMPARATOR
Intervention: Premixed insulin (insulin aspart/insulin aspart protamine 30/70 starting with 6IU twice daily)
Number of subjects: 0
Study 24710917 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 50
Study 24710917 — intervention group
Group type: COMPARATOR
Intervention: No nicotine gum (control)
Number of subjects: 50
Study 23314694 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 μg/kg fentanyl
Number of subjects: 90
Study 23314694 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 μg/kg fentanyl
Number of subjects: 90
Study 23314694 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 90
Study 20498403 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg plus docetaxel 100 mg/m(2)
Number of subjects: 736
Study 20498403 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg plus docetaxel 100 mg/m(2)
Number of subjects: 736
Study 20498403 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 100 mg/m(2) plus placebo
Number of subjects: 736
Study 20498403 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Number of subjects: 736
Study 20498403 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg
Number of subjects: 736
Study 19098989 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly artesunate plus amodiaquine (AS+AQ)
Number of subjects: 2451
Study 19098989 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimonthly sulphadoxine-pyrimethamine (SP)
Number of subjects: 2451
Study 19098989 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimonthly artesunate plus amodiaquine (AS+AQ)
Number of subjects: 2451
Study 19098989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2451
Study 15908136 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported substance abuse treatment contact after enrollment
Number of subjects: 525
Study 15908136 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical evidence of continued cocaine use
Number of subjects: 525
Study 15908136 — intervention group
Group type: EXPERIMENTAL
Intervention: Race, hair cocaine level, and opiates in hair
Number of subjects: 525
Study 14620390 — intervention group
Group type: EXPERIMENTAL
Intervention: Trizivir
Number of subjects: 195
Study 14620390 — intervention group
Group type: COMPARATOR
Intervention: Combivir-ABC
Number of subjects: 195
Study 10720292 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 271
Study 10720292 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 271
Study 10720292 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (both doses)
Number of subjects: 271
Study 10720292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 8704682 — intervention group
Group type: EXPERIMENTAL
Intervention: BU/CY2 conditioning regimen
Number of subjects: 52
Study 8704682 — intervention group
Group type: EXPERIMENTAL
Intervention: BU/CY2 conditioning regimen with T cell depletion
Number of subjects: 52
Study 1465034 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17 beta‐oestradiol and different doses of progesterone (50, 100 or 200 mg)
Number of subjects: 30
Study 3882774 — intervention group
Group type: EXPERIMENTAL
Intervention: clovoxamine
Number of subjects: 42
Study 3882774 — intervention group
Group type: COMPARATOR
Intervention: amitriptyline
Number of subjects: 42
Study 30629675 — intervention group
Group type: EXPERIMENTAL
Intervention: New PermaNet2.0 LLINs distributed to households in October 2014
Number of subjects: 17142
Study 30629675 — intervention group
Group type: EXPERIMENTAL
Intervention: LLIN use during the first year (week 1-52)
Number of subjects: 17142
Study 30629675 — intervention group
Group type: EXPERIMENTAL
Intervention: LLIN use during the second year (week 53-104)
Number of subjects: 17142
Study 30629675 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group comparison for LLIN use
Number of subjects: 17142
Study 30629675 — intervention group
Group type: EXPERIMENTAL
Intervention: Household head educational status comparison for LLIN use
Number of subjects: 17142
Study 30629675 — intervention group
Group type: EXPERIMENTAL
Intervention: Family size comparison for LLIN use
Number of subjects: 17142
Study 29907581 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 12221
Study 29907581 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 12221
Study 29907581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12221
Study 29907581 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg (EMPA-REG H2H-SU trial)
Number of subjects: 12221
Study 29907581 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (EMPA-REG H2H-SU trial)
Number of subjects: 12221